AI Article Synopsis

  • The ZEPHIR clinical trial aimed to assess how [89Zr]trastuzumab-PET/CT and [18F]FDG-PET/CT can predict outcomes in patients with advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1).
  • Researchers integrated imaging data from PET/CT scans and gene expression data from biopsy samples to understand the relationship between drug uptake and biological processes in the tumors.
  • The study revealed that low uptake of [89Zr]trastuzumab was linked to ECM-related gene pathways, while high uptake correlated with immune responses, highlighting the importance of ECM in affecting drug uptake and treatment response in these patients.

Article Abstract

Purpose: The ZEPHIR clinical trial evaluated the role of [89Zr]trastuzumab-PET/CT (HER2-PET/CT) and 2-[18F]fluoro-2-deoxy-D-glucose PET/CT ([18F]FDG-PET/CT) in predicting outcomes in patients with advanced HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1). Here, we combined molecular/metabolic imaging and transcriptomic data to investigate the biological processes associated with [89Zr]trastuzumab and [18F]FDG uptake, and to dissect the mechanisms involved in T-DM1 resistance.

Experimental Design: RNA was extracted from metastasis biopsies obtained in the ZEPHIR trial. HER2-PET/CT and [18F]FDG-PET/CT imaging data of biopsied lesions were integrated with transcriptomic data. Lesions were compared based on the level of [89Zr]trastuzumab uptake as well as on the presence/absence of metabolic response, defined comparing baseline and on-treatment [18F]FDG-PET/CT.

Results: We analyzed matched transcriptomic and molecular/metabolic imaging data for 24 metastases. Genes and pathways involved in extracellular matrix (ECM) organization and glycosylphosphatidylinositol synthesis were enriched in lesions presenting low [89Zr]trastuzumab uptake. [18F]FDG uptake at baseline correlated with proliferation and immune-related processes. Hypoxia and ECM-related processes were enriched in lesions showing no metabolic response to T-DM1, while immune-related processes were associated with high [89Zr]trastuzumab uptake and metabolic response. Gene signatures including differentially expressed genes according to [89Zr]trastuzumab uptake and metabolic response showed predictive value in an external cohort.

Conclusions: To our knowledge, this study represents the first correlative analysis between [89Zr]trastuzumab tumor uptake and gene expression profiling in humans. Our findings suggest a role of ECM in impairing [89Zr]trastuzumab tumor uptake and T-DM1 metabolic response in advanced HER2-positive breast cancer, highlighting the potential of molecular imaging to depict tumor microenvironment features.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-24-1007DOI Listing

Publication Analysis

Top Keywords

metabolic response
20
[89zr]trastuzumab uptake
16
advanced her2-positive
12
her2-positive breast
12
breast cancer
12
molecular imaging
8
imaging transcriptomic
8
trastuzumab emtansine
8
emtansine t-dm1
8
zephir clinical
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!